Hormones, blood levels and open questions
These papers sit beside the CJC-1295 and ipamorelin pages. They help separate a hormone change from a useful result in everyday life. The FDA reviews add safety concerns and explain the limits of the human evidence.
- CJC-1295 in healthy adults Teichman and colleagues · 2006
A small study of the long-acting DAC form in healthy adults. It measured blood levels and hormones, not better sleep or faster recovery.
- Growth hormone pulses during CJC-1295 exposure Ionescu and Frohman · 2006
Growth hormone still rose and fell in pulses in healthy men. That is a hormone finding, not a measure of how someone felt.
- FDA review of the different CJC-1295 forms FDA · December 2024
Explains the DAC distinction and safety concerns. FDA found no human study of no DAC; the result for one form can't cover both.
- FDA safety concerns for compounding ingredients FDA · page current as of April 22, 2026
CJC-1295 is nominated but withdrawn. Ipamorelin acetate also remains in Category 2 for 503B outsourcing facilities. Withdrawal isn't clearance; the separate tables matter.
- Ipamorelin in healthy male volunteers Gobburu and colleagues · 1999
The roughly two-hour half-life came from infusions into a vein in healthy men. The route and people belong beside the number.
- Ipamorelin after bowel surgery Beck and colleagues · 2014
Asked whether adults could tolerate a meal sooner after bowel surgery. The main result didn't show a statistically significant benefit over a dummy treatment.
- FDA review of ipamorelin FDA · October 2024
Covers immune concerns and missing long-term safety work. It discusses serious events in surgery research without establishing that ipamorelin caused them.
Semaglutide during treatment and after
The weight trial, its follow-up and the heart trial ask different questions. They can sit beside each other without merging their participants or turning an average into a prediction.
- Semaglutide over 68 weeks in STEP 1 Wilding and colleagues · 2021
Measured weight over 68 weeks in adults with excess weight and without diabetes. Both groups had lifestyle support. The result is a group average.
- Weight after semaglutide was stopped Wilding and colleagues · 2022
Followed a smaller group after semaglutide and structured lifestyle support stopped. Much of the lost weight returned; this adds a later view to the first result.
- Semaglutide and cardiovascular events in SELECT Lincoff and colleagues · 2023
Studied cardiovascular events in adults who already had cardiovascular disease and excess weight, without diabetes. That group matters when reading the result.
- Wegovy (semaglutide) prescribing information DailyMed · semaglutide label
Keeps the approved product's uses and warnings together, including stomach problems and the boxed thyroid warning. A label isn't a personal assessment.
Tesamorelin over minutes and months
The label and follow-up keep the specific approved use in view. They also show why blood duration and the time a result lasts aren't the same thing.
The comparison page brings these questions together. It leaves the papers’ limits attached to their findings.
- Egrifta WR (tesamorelin) prescribing information DailyMed · tesamorelin label
Gives the specific HIV-related use, the short blood half-life and the blood sugar, growth-signal and fluid-retention warnings. It isn't a weight-loss label.
- Tesamorelin with a safety extension Falutz and colleagues · 2010
Followed adults with HIV and excess abdominal fat. Deep abdominal fat returned after a switch to a dummy treatment, so the later view matters.